<DOC>
	<DOCNO>NCT02633293</DOCNO>
	<brief_summary>This multicenter , open-label trial evaluate safety efficacy inhale treprostinil subject pre-capillary pulmonary hypertension ( PH ) associate interstitial lung disease ( ILD ) include combine pulmonary fibrosis emphysema ( CPFE ) . The study include 266 patient complete required assessment RIN-PH-201 study approximately 100 clinical trial center . The study continue Your participation study voluntary last discontinue study study end . The study continue subject reach Week 108 visit inhale treprostinil become commercially available patient PH associate ILD include CPFE ( whichever sooner ) .</brief_summary>
	<brief_title>An Open Label Extension Study Evaluate Inhaled Treprostinil Adult PH With ILD Including CPFE</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>1 . Subject voluntarily give informed consent participate study . 2 . The subject participate study RINPH201 , remain study drug , compliant RINPH201 study procedure enrol study RINPH201 time study discontinue sponsor . 3 . Females reproductive potential must nonpregnant ( confirm urine pregnancy test Baseline ) nonlactating , : Either abstain intercourse ( line prefer usual lifestyle ) , Use two medically acceptable , highlyeffective form contraception duration study , least 30 day discontinue study drug . 4 . Males must use condom duration treatment least 48 hour discontinue study drug . 1 . The subject pregnant lactating . 2 . The subject prematurely discontinue study RINPH201 . 3 . The subject develop concurrent illness condition conduct RINPH201 , opinion Investigator , would represent risk overall health enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Treprostinil</keyword>
	<keyword>PH</keyword>
	<keyword>ILD</keyword>
	<keyword>CPFE</keyword>
	<keyword>6 Minute Walk Test</keyword>
</DOC>